<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111162</url>
  </required_header>
  <id_info>
    <org_study_id>Upenn HIV-H1N1-001</org_study_id>
    <nct_id>NCT01111162</nct_id>
  </id_info>
  <brief_title>H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients</brief_title>
  <official_title>Evaluating the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to study influenza vaccine responses in HIV infected
      individuals. Immunocompromised individuals require special protection from influenza, but may
      not respond appropriately to the standard killed vaccine. Patients who receive the H1N1 flu
      vaccine as part of their standard of care will be asked to donate blood samples for
      immunologic studies. These studies will determine whether participants were able to produce
      the appropriate antibodies to the vaccine and possibly identify predictors of vaccine
      responsiveness.

      Our hypothesis is that vaccine responsiveness to the new H1N1 influenza vaccine will be
      compromised in HIV infected patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>21-28 days</time_frame>
    <description>To assess the safety of inactivated swine-origin H1N1 influenza vaccine in HIV-1 infected individuals (received as part of standard of care).
Safety was assessed via
Adverse Events of Grade 3 or higher of abnormal laboratory values, signs and symptoms or diagnoses.
Solicited local AEs, including pain, tenderness, redness, and swelling post each vaccination. Solicited systemic AEs, including feverishness, malaise, body aches (exclusive of the injection site), nausea, and headache post each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>21-28 days</time_frame>
    <description>Immunologic response, defined as HAI titer ≥ 1:40, at 21 days after vaccine dose.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H1N1 vaccination</intervention_name>
    <description>Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A confirmed diagnosis of HIV-1 infection as documented by any licensed ELISA test kit
             and confirmed by Western blot at any time prior to study entry or any measurable HIV
             RNA viral load in the chart. Serum HIV-1 antigen, plasma HIV-1 RNA, or a second
             antibody test by a method other than ELISA is acceptable as an alternative
             confirmatory test.

          2. &gt; 18 years

          3. Able to understand and comply with planned study procedures.

          4. Provides written informed consent prior to initiation of any study procedures.

          5. Subject should be 1) on stable antiretroviral therapy as outlined in the DHHS
             treatment guidelines for HIV-1 infected individuals OR 2) not on antiretroviral
             therapy and not intending to start treatment within the next 30 days.

        Exclusion Criteria:

          1. Has a known allergy to eggs or other components in the vaccines (these may include,
             but are not limited to: gelatin, formaldehyde, octoxinol and chicken protein).

          2. Has a history, in the opinion of the site investigator, of severe reactions following
             previous immunization with seasonal TIV.

          3. Participation in a novel H1N1 influenza vaccine study in the past two years.

          4. Proven history, by RT-PCR, of novel influenza H1N1 infection, or, has a positive
             influenza diagnostic testing since June 2009 (specificity to H1N1 not required) prior
             to study entry.

          5. Received any other live licensed vaccine within 4 weeks or inactivated licensed
             vaccine within 1 week prior to study entry.

          6. Scheduled administration of any live virus vaccine or inactivated vaccine at or
             between entry and the Day 21 visit. NOTE: Live or inactivated vaccines expected to be
             administered between study entry and the Day 21 visit should be excluded to prevent
             potential interference with immunogenicity responses and confounding safety results.
             Regular seasonal flu vaccination will be allowed if is separated more than 7 days from
             the administration of the H1N1 vaccine.

          7. Received a non-licensed agent (vaccine, drug, biologic, device, blood product, or
             medication) within 4 weeks prior to vaccination in this study

          8. An acute illness and/or an oral temperature greater than or equal to 100.0 degrees F
             within 24 hours prior to study entry.

          9. Use of anti-cancer chemotherapy or radiation therapy within the preceding 36 months of
             study enrollment, or has immunosuppression as a result of an underlying illness or
             treatment (other than HIV-1 infection).

         10. Active neoplastic disease (excluding non-melanoma skin cancer, and HPV-related
             cervical dysplasia, CIN grades 1, 2 or 3).

         11. Long term use of glucocorticoids, including oral or parenteral prednisone or
             equivalent (more than 2.0 mg/kg per day or more than 20 mg total dose) for more than 2
             consecutive weeks (or 2 weeks total) in the past 3 months, or high-dose inhaled
             steroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent) within the past 3
             months (nasal and topical steroids are allowed).

         12. Received immunoglobulin or other blood products

         13. Current diagnosis of uncontrolled major psychiatric disorder.

         14. History of Guillain-Barré Syndrome in the subject or subject's family (parents,
             siblings, half siblings, or children).

         15. Any condition that would, in the opinion of the site investigator, place the subject
             at an unacceptable risk of injury or render the subject unable to meet the
             requirements of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Tebas</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania. Clinical Trials Unit</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, Kenney T, Kappes R, Wagner W, Maffei K, Sullivan K; Center for AIDS Research and Clinical Trials Unit of the University of Pennsylvania. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS. 2010 Sep 10;24(14):2187-92. doi: 10.1097/QAD.0b013e32833c6d5c.</citation>
    <PMID>20616698</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <results_first_submitted>June 5, 2016</results_first_submitted>
  <results_first_submitted_qc>June 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2016</results_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Pablo Tebas</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>H1N1 vaccination</keyword>
  <keyword>HIV infected individuals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at the MacGregor Clinic of the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, USA, between the months of November and January 2009–2010. All patients signed an informed consent. The study was approved by the University of Pennsylvania institutional review board .</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vaccine Arm (Single Arm)</title>
          <description>15 µg dose of the monovalent, unadjuvanted, inactivated, split virus H1N1 vaccine (Novartis, Basel, Switzerland).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vaccination Group (Single Arm Study)</title>
          <description>All participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="40" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants at Baseline with HAI assay titers ≥ 1:40</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety</title>
        <description>To assess the safety of inactivated swine-origin H1N1 influenza vaccine in HIV-1 infected individuals (received as part of standard of care).
Safety was assessed via
Adverse Events of Grade 3 or higher of abnormal laboratory values, signs and symptoms or diagnoses.
Solicited local AEs, including pain, tenderness, redness, and swelling post each vaccination. Solicited systemic AEs, including feverishness, malaise, body aches (exclusive of the injection site), nausea, and headache post each vaccination.</description>
        <time_frame>21-28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vacinees</title>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>To assess the safety of inactivated swine-origin H1N1 influenza vaccine in HIV-1 infected individuals (received as part of standard of care).
Safety was assessed via
Adverse Events of Grade 3 or higher of abnormal laboratory values, signs and symptoms or diagnoses.
Solicited local AEs, including pain, tenderness, redness, and swelling post each vaccination. Solicited systemic AEs, including feverishness, malaise, body aches (exclusive of the injection site), nausea, and headache post each vaccination.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity</title>
        <description>Immunologic response, defined as HAI titer ≥ 1:40, at 21 days after vaccine dose.</description>
        <time_frame>21-28 days</time_frame>
        <population>Among the 90 participants without evidence of previous exposure to H1N1, only 61% [95% confidence interval (CI) 51–71] developed protective titers by week 3 of the study (seroconversion rate).</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Arm (Single Arm)</title>
            <description>15 µg dose of the monovalent, unadjuvanted, inactivated, split virus H1N1 vaccine (Novartis, Basel, Switzerland).</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity</title>
          <description>Immunologic response, defined as HAI titer ≥ 1:40, at 21 days after vaccine dose.</description>
          <population>Among the 90 participants without evidence of previous exposure to H1N1, only 61% [95% confidence interval (CI) 51–71] developed protective titers by week 3 of the study (seroconversion rate).</population>
          <units>percentage of seroconversion</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="51" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of the study (21-28 days)</time_frame>
      <desc>Serious adverse events include all Grade 3 or greater adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Vaccine Arm (Single Arm)</title>
          <description>15 µg dose of the monovalent, unadjuvanted, inactivated, split virus H1N1 vaccine (Novartis, Basel, Switzerland).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at Injection Site</sub_title>
                <description>Administration site reaction</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Redness at Injection Site</sub_title>
                <description>Administration site reaction</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Tenderness at Injection Site</sub_title>
                <description>Administration site reaction</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Systemic site reaction</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Systemic site reaction</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Systemic site reaction</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systemic site reaction</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Systemic site reaction</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Systemic site reaction</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Systemic site reaction</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single Arm Study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pablo Tebas</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>2153498092</phone>
      <email>pablo.tebas@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

